Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial

被引：0
|
作者：
Hong, C. -H. [1 ]
Wu, T. [2 ]
Calimlim, B. [2 ]
Teixeira, H. [2 ]
de Bruin-Weller, M. [3 ]
机构：
[1] Univ British Columbia, Dept Dermatol & Skin Sci & Prob Med Res, Surrey, BC, Canada
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Atopic dermatitis; Pruritus; Upadacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P011
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis
    Hamilton, J.
    Hamon, S.
    Simpson, E.
    Chaudhry, U.
    Swanson, B.
    Zhang, R.
    Graham, N.
    Pirozzi, G.
    Ardeleanu, M.
    Rizova, E.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S224 - S224
  • [22] Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial
    Guttman-Yassky, E.
    Bahadori, L.
    Brooks, L.
    Clark, K. L.
    Grindebacke, H.
    Ho, C. N.
    Katial, R.
    Pham, T. -H.
    Walton, C.
    Datto, C. J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : E1211 - E1214
  • [23] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [24] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    [J]. Dermatology and Therapy, 2023, 13 : 595 - 608
  • [25] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study
    Kimball, Alexa B.
    Ackerman, Lindsay
    Schlosser, Bethanee J.
    Prajapati, Vimal H.
    Fretzin, Scott
    Takahashi, Hidetoshi
    Zhan, Tianyu
    Huang, Xiaohong
    Camp, Heidi S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB42 - AB42
  • [26] The impact of severity of atopic dermatitis on patient-reported outcomes of adults with moderate-to-severe atopic dermatitis
    Vietri, Jeffrey
    Nyberg, Fredrik
    Varol, Nebibe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB254 - AB254
  • [27] Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial
    Tsianakas, A.
    Luger, T. A.
    Radin, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 406 - 414
  • [28] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
    Silverberg, Jonathan I.
    Cohen, Arnon D.
    Stander, Sonja
    Feeney, Claire
    Valdez, Hernan
    Biswas, Pinaki
    Cameron, Michael C.
    DiBonaventura, Marco
    Gerber, Robert A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [29] Effects of Oral Tofacitinib on Patient-Reported Outcomes in Patients With Moderate to Severe Crohn's Disease: Results of Two Phase 2B Randomized Placebo-Controlled Trials
    Panes, Julian
    Chan, Gary
    Maller, Eric
    Moscariello, Michele
    Wang, Wenjin
    Healey, Paul J.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [30] Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
    Thaci, Diamant
    Simpson, Eric L.
    Beck, Lisa A.
    Bieber, Thomas
    Blauvelt, Andrew
    Papp, Kim
    Soong, Weily
    Worm, Margitta
    Szepietowski, Jacek C.
    Sofen, Howard
    Kawashima, Makoto
    Wu, Richard
    Weinstein, Steven P.
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Teper, Ariel
    Sutherland, E. Rand
    Mastey, Vera
    Stahl, Neil
    Yancopoulos, George D.
    Ardeleanu, Marius
    [J]. LANCET, 2016, 387 (10013): : 40 - 52
12345